Gyntools was showcased at the European Healthtech Investment Forum 2023 in Helsinki, Finland. Among the 41 selected companies from over 200 applicants. Gyntools was chosen as one of the top 8 companies! by the panel of attending investor experts!
Vaginitis affects most women at least once in their lifetime, yet 50% of initial clinic visits result in misdiagnosis. Motivated by the need for faster, more accurate, and accessible diagnosis, Gyntools developed Gyni™, a deep-learning, AI-based diagnostic platform that revolutionizes vaginitis diagnosis. As the most common feminine medical condition, it is crucial to address the high misdiagnosis rate.
Gyni™ offers an automated, patient-centric solution designed to diagnose various causes of vaginal inflammation, including discharge, itching, or pain. This innovative approach significantly improves the initial evaluation of vaginitis, providing point-of-care diagnosis, guiding more appropriate treatment, reducing healthcare costs, and enhancing patients’ quality of life.
Capable of diagnosing seven vaginitis conditions from a single swab within five minutes, Gyni™ can diagnose 7 (seven) vaginitis conditions from a single swab within 5 (five) minutes: Bacterial Vaginosis (BV), Candida Albicans (CA), Candida Non-Albicans (CNA), Trichomoniasis (TV), Vaginal Atrophy, Desquamative Inflammatory Vaginitis (DIV) and Cytolytic Vaginosis (CV).
Gyntools has initiated the marketing of Gyni™ in Europe and Israel and has secured three contracts with local dealers in Switzerland, Belgium, and S. Korea. The company has received the CE mark in Europe, granting clearance for marketing in Europe and the AMAR clearance from the Israeli Ministry of Health’s medical device regulation unit. Gyntools is in discussion with all the Israeli HMOs regarding GYNI and continues its pilot study which started last year in March with the IDF continues.
With a fundraising goal of $5 million, Gyntools has already secured $1.2 million. The main use of funds will be directed toward FDA-related clinical trials, commercialization, and market development. Gyntools is an alumnus of the Swiss accelerator Tech4eva and MassChallenge accelerator
Established in 2018, Gyntools is led by an exceptional team that includes Prof Ahinoam Lev Sagie, MD, senior OB-GYN (CMO), Nimrod Lev (CEO), and Meny Lev Sagie (CTO). Prof. Ahinoam Lev-Sagie, a senior OB-GYN recognized the high demand for her service. With a passion to help the women suffering she turned to her brother (Nimrod) and husband (Meny) to help the situation. The company spent its first two years researching the market and analyzing data. In 2019 the company received its first seed investment which was followed by receiving an Israel Investment Authority grant to fully develop the technology. Most of the investors were Israeli gynecologists that are familiar with the problem that Gyntools solves.
Gyntools has been granted three (3) US patents, an Israeli patent, and a Japanese patent, which protect its first two pipeline devices.
For further information:
Nimrod Lev, nimrod AT gyntools.com Gyntools
Learn more: https://youtu.be/MvL9aGm6B7A
About JLM- BioCity
News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/. Join the JLM-BioCity LinkedIn group at https://www.linkedin.com/groups/7060787 https://www.linkedin.com/groups/7060787 to get the news updates sent to you and to be part of the JLM-BioCity community.
JLM- BioCity is a non-profit organization focused on developing and excelling in Jerusalem’s bio-community.
We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.
If you want your company featured in our blogs, or news releases, please contact: info AT jlm-biocity.org